- Schuster MG, Edwards JE Jr., Sobel JD, et al. Empirical fluconazole versus placebo for intensive care
unit patients. A randomized trial. Ann Intern Med 2008; 149:83–90. - McCabe WR, Jackson GG. Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic
observations. Arch Intern Med 1962; 110:856–864. - Ferreira FL, Bota DP, Bross A, et al. Serial evaluation of the SOFA score to predict outcome in critically
ill patients. JAMA 2001; 286:1754–1758. - Byl B, Clevenvbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological
data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60–66. - Trouillet JL, Vuagnat A, Combes A, et al. Pseudomonas aeruginosa ventilator-associated pneumonia:
comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin
Infect Dis 2002; 34:1047–1054. - Lockhart SR, Abramson MA, Beckmann SE, et al. Antimicrobial resistance among gram-negative
bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004.
J Clin Microbiol 2007; 45:3352–3359. - Young LS, Martin WJ, Meyer RD, et al. Gram-negative rod bacteremia: microbiologic, immunologic,
and therapeutic considerations. Ann Intern Med 1977; 86:456–471. - Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-
resistant bacteria. Am J Respir Crit Care Med 1998; 157:531–539. - Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with
pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic
prescription. Am J Respir Crit Care Med 2000; 162:505–511. - Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia.
Crit Care Med 2004; 32:2183–2190. - Omidvari K, de Boisblanc BP, Karam G, et al. Early transition to oral antibiotic therapy for
community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir
Med 1998; 92:1032–1039. - Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral
antibiotic conversion. Pharmacotherapy 1997; 17:271–276. - Li JZ, Willke RJ, Rittenhouse BE, et al. Effect of linezolid versus vancomycin on length of hospital stay
in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-
resistant staphylococci: results from a randomized clinical trial. Surg Infect 2003; 4:57–70. - Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients
receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41:1159–1166. - Bhavnani S, Hammel JP, Cirincione BB, et al. Use of pharmacokinetic-pharmacodynamic target
attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents
Chemother 2005; 49:3944–3947. - Lacy MD, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect
Dis 1998; 27:23–27. - Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily Aminoglycoside Program
administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39:650–655. - Kollef MH, Napolitano LM, Solomkin JS, et al. Health Care–Associated Infection (HAI): a critical
appraisal of the emerging threat—proceedings of the HAI summit. Clinical Infectious Diseases 2008;
47:S55–S99. - Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double blind
studies of patients with MRSA nosocomial pneumonia. Chest 2003; 124(5):1789–1797. - Potoski BA, Mangino JE, Goff DA. Clinical failures of linezolid and implications for the clinical
microbiology laboratory. Emerg Infect Dis 2002; 8:1519–1520. - Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus
aureus. Lancet 2001; 358:207–208. - Fowler VG Jr., Boucher HW, Corey GR, et al.; for the S. aureus Endocarditis and Bacteremia Study
Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylo-
coccus aureus. N Engl J Med 2006; 355:653–665. - Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on
infectious mortality in an intensive care unit. Crit Care Med 2001; 29(6):1101–1108. - Peche`re JC. Rotating antibiotics in the intensive care unit: feasible, apparently beneficial, but questions
remain. Crit Care 2002; 6:9–10.
496 Ahuja et al.